171 related articles for article (PubMed ID: 23307241)
21. Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
Chen H; Yao W; Chu Q; Han R; Wang Y; Sun J; Wang D; Wang Y; Cao M; He Y
Cancer Lett; 2015 Dec; 369(1):97-102. PubMed ID: 26341687
[TBL] [Abstract][Full Text] [Related]
22. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
24. Modified Glasgow Prognostic Score as a Prognostic Factor in Patients with Extensive Disease-Small-Cell Lung Cancer: A Retrospective Study in a Single Institute.
Sonehara K; Tateishi K; Komatsu M; Yamamoto H; Hanaoka M; Kanda S; Koizumi T
Chemotherapy; 2019; 64(3):129-137. PubMed ID: 31622969
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
[TBL] [Abstract][Full Text] [Related]
26. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
Ragavan M; Das M
Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
[TBL] [Abstract][Full Text] [Related]
27. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.
Belani CP; Brodowicz T; Ciuleanu TE; Krzakowski M; Yang SH; Franke F; Cucevic B; Madhavan J; Santoro A; Ramlau R; Liepa AM; Visseren-Grul C; Peterson P; John WJ; Zielinski CC
Lancet Oncol; 2012 Mar; 13(3):292-9. PubMed ID: 22336221
[TBL] [Abstract][Full Text] [Related]
28. Expressions of topoisomerase IIα and BCRP in metastatic cells are associated with overall survival in small cell lung cancer patients.
Rijavec M; Silar M; Triller N; Kern I; Cegovnik U; Košnik M; Korošec P
Pathol Oncol Res; 2011 Sep; 17(3):691-6. PubMed ID: 21455636
[TBL] [Abstract][Full Text] [Related]
29. Prolonged progression-free survival and overall survival are associated with diabetes mellitus but inversely associated with levels of blood glucose in patients with lung cancer.
Wang NF; Tang HM; Liu FL; Hong QY
Chin Med J (Engl); 2020 Apr; 133(7):786-791. PubMed ID: 32195672
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
Kong Q; Wang XY; Jiang RC; Ba Y; Li K
Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
[TBL] [Abstract][Full Text] [Related]
31. Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer.
Imai H; Mori K; Watase N; Kazama T; Fujimoto S; Kaira K; Yamada M; Minato K
Thorac Cancer; 2016 Nov; 7(6):655-662. PubMed ID: 27755823
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer.
Imai H; Kaira K; Mori K; Ono A; Akamatsu H; Matsumoto S; Taira T; Kenmotsu H; Harada H; Naito T; Murakami H; Endo M; Nakajima T; Yamada M; Takahashi T
BMC Cancer; 2015 Dec; 15():989. PubMed ID: 26690494
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia.
Shirasawa M; Fukui T; Kusuhara S; Hiyoshi Y; Nakahara Y; Nishinarita N; Igawa S; Naoki K
BMC Cancer; 2019 Feb; 19(1):163. PubMed ID: 30808322
[TBL] [Abstract][Full Text] [Related]
34. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
[TBL] [Abstract][Full Text] [Related]
35. [Recent progress in chemotherapy for advanced lung cancer].
Negoro S; Fukuoka M
Gan To Kagaku Ryoho; 1995 Mar; 22(4):451-60. PubMed ID: 7887637
[TBL] [Abstract][Full Text] [Related]
36. Survival of patients with small cell lung carcinoma in Taiwan.
Kuo YH; Lin ZZ; Yang YY; Shao YY; Shau WY; Kuo RN; Yang JC; Lai MS
Oncology; 2012; 82(1):19-24. PubMed ID: 22269348
[TBL] [Abstract][Full Text] [Related]
37. The preoperative HbA1c level is an independent prognostic factor for the postoperative survival after resection of non-small cell lung cancer in elderly patients.
Motoishi M; Sawai S; Hori T; Yamashita N
Surg Today; 2018 May; 48(5):517-524. PubMed ID: 29222669
[TBL] [Abstract][Full Text] [Related]
38. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes.
Tan BX; Yao WX; Ge J; Peng XC; Du XB; Zhang R; Yao B; Xie K; Li LH; Dong H; Gao F; Zhao F; Hou JM; Su JM; Liu JY
Cancer; 2011 Nov; 117(22):5103-11. PubMed ID: 21523768
[TBL] [Abstract][Full Text] [Related]
39. Reirradiation for locoregionally recurrent lung cancer: outcomes in small cell and non-small cell lung carcinoma.
Kruser TJ; McCabe BP; Mehta MP; Khuntia D; Campbell TC; Geye HM; Cannon GM
Am J Clin Oncol; 2014 Feb; 37(1):70-6. PubMed ID: 23357968
[TBL] [Abstract][Full Text] [Related]
40. Impact of severe-to-very severe chronic obstructive pulmonary disease on the prognosis of patients with non-small cell lung cancer who received chemotherapy.
Dong W; Zhu Y; Du Y; Wang L; Feng X; Ma S
Clin Respir J; 2020 Apr; 14(4):345-352. PubMed ID: 31876095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
